Make waves
COMMUNITY EDUCATION DAY

BREAK THE SILENCE.
Mental Health and Genetics: An Overview of What We Know

Jen Milau, APRN, PMHNP-BC
Psychiatric Mental Health Nurse Practitioner
Objectives

• Address link between genetics and psychiatric diagnoses
• Review psychiatric pharmacogenomic panels available
• Discuss advantages of obtaining pharmacogenetic results and clarify misconceptions about clinical utility / relevance
• Open panel for questions
The Link Between Genetics and Mental Illness

A Review of Current Research and Theories
Mental Illness and Heritability

Theory that a link exists has been supported by:

• Clustering of illness in families
• Higher concordance rates between monozygotic than dizygotic twins
• Similarity of adoptee to their biological rather than adoptive relatives

(Uher, 2009)
Diagnoses with Suspected Genetic Link

- Schizophrenia
- Obsessive-compulsive Disorder
- Bipolar Spectrum Disorders
- Anxiety Disorders
- Major Depressive Disorder
- Autism Spectrum Disorder
- Attention-deficit Hyperactivity Disorder
- Eating Disorders (Anorexia Nervosa, Bulimia Nervosa)
Current Research

• Research Domain Criteria (RDoC) – NIMH
  • Research framework for new approaches to investigating mental disorders
  • Genetics is major area of interest under study
    • Limitations due to access/availability for genome-wide association studies

• 2013: NIH-funded team conducted largest genome-wide study of its kind
  • Discovered that people with disorders traditionally thought to be distinct – autism, ADHD, bipolar disorder, major depression and schizophrenia – were more likely to have suspect genetic variation at the same four chromosomal sites.

(The Lancet, 2013)
Limitations to Current Technology

• At this point there are no identified alterations to genes which consistently predict development of specific mental illness (NIMH, 2017)

• No genetic tests available which accurately predict risk of mental illness based upon genome scans or karyotyping
“Causes” of Mental Illness

• Multi-factorial
  • Genetic
  • Neurobiological
  • Environmental Exposures
  • Life experiences
    • Trauma
    • Attachment / Neglect
  • Culture
  • Relationships
Epigenetics

• Genetic control by factors other than an individual's DNA sequence (genotype) which can alter an individual’s gene function (phenotype)

• Can switch genes on or off and determine which proteins are transcribed – “Gene silencing”
  • Methylation / Demethylation
    • Adding or Removal of Methyl group to DNA to modify the function and expression of a gene
  • Histone Changes
    • Modifications to arrangement of chromatin (area in cell nucleus that makes up complex of DNA and proteins)
  • RNA-Associated Silencing

(Simmons, 2008)
Epigenetics and Mental Illness

• Genetic susceptibility coupled with environmental factors – turn genes “on” or “off” leading to changes in gene expression (phenotype)
  • Diet / Nutrition
  • Stress
  • Exposure to Toxins or Substances
    • In-utero
    • Childhood
    • Adulthood
  • Early Adverse Life Events
  • Neglect / Lack of Attachment

(Klengel & Binder, 2015)
Pharmacogenomic Testing

Implications and Limitations
What is Pharmacogenomic Testing?

• Pharmacogenomics: Study of how a person’s genes affect their response to medications
  • Pharmacology: Study of use / effects of drugs
  • Genomics: Study of genes and their functions

• Information available to help personalize treatment
  • Efficacy
  • Side Effects
  • Dosing and Titration

• Asthma, HIV, Pain medications/anesthesia, Cancer, Heart Disease, Psychiatric Disorders

Pharmacogenomics is in its infancy!
Terminology

• Pharmacokinetics (What the body does to a drug)
  • Absorption, distribution, metabolism, and excretion.
  • Helps with understanding of dose and associated response

• Pharmacodynamics (What the drug does to the body)
  • Biochemical, physiologic, and molecular effects of drugs on the body
  • Involves receptor binding (including receptor sensitivity), post-receptor effects, and chemical interactions.
Research Backing

• **Clinical Pharmacogenetics Implementation Consortium (CPIC)**
  
  - Started as shared project between PharmGKB and Pharmacogenomics Research Network (PGRN) in 2009. CPIC guidelines are indexed in PubMed as clinical guidelines, endorsed by ASHP and ASCPT, and referenced in ClinGen and PharmGKB
  
  - Goal = Address barrier to clinical implementation of pharmacogenomic tests
    - Freely available
    - Peer-reviewed
    - Evidence-based
    - Detailed gene/drug clinical practice guidelines

• **Pharmacogenetic Working Group (PWG)**
  
  - 85 genotype and phenotype drug combinations for 25 medications (this number is likely higher at this point in time)
  
  - Available on the PharmGKB site
  
  - Translate phenotype and genotype information into therapeutic dose recommendations.
  
  - Information re: clinical relevance provided with clearly stated level of the evidence (strong, moderate, and optional).

(CPIC, 2019; Drozda et al., 2014)
How is the Information Used?

• Language now being included on FDA product labeling for certain psychotropic medications!
  • Table of Pharmacogenomic Biomarkers in Drug Labeling available on FDA website:
    https://www.fda.gov/drugs/scienceresearch/ucm572698.htm

• Pharmacogenetic / Pharmacogenomic Test Products
  • Many available – Over 20 companies with different panels
    • FDA currently increasing scrutiny
  • Algorithm-Based – Varying Evidence
  • GeneSight (AssureRx Health) has most substantial evidence base in regards to clinical trials and outcomes

(Zeier, et al., 2018)
# Antidepressants

**Use as directed**
- Desvenlafaxine (Pristiq®)
- Vilazodone (Viibryd®)

**Use with caution**
- Amitriptyline (Elavil®)[3,8]
- Citalopram (Celexa®)[3,4]
- Doxepin (Sinequan®)[3,8]
- Escitalopram (Lexapro®)[3,4]
- Fluvoxamine (Luvox®)[3,7,8]
- Sertraline (Zoloft®)[4]
- Trazodone (Desyrel®)[1]
- Venlafaxine (Effexor®)[3]

**Use with increased caution and with more frequent monitoring**
- Bupropion (Wellbutrin®)[1,6]
- Clomipramine (Anafranil®)[3,7,8]
- Desipramine (Norpramin®)[1,6,8]
- Duloxetine (Cymbalta®)[3,7,8]
- Fluoxetine (Prozac®)[1,6]
- Imipramine (Tofranil®)[1,6,8]
- Mirtazapine (Remeron®)[3,7]
- Nortriptyline (Pamelor®)[1,3,8]
- Paroxetine (Paxil®)[1,4,6,8]
- Selegiline (Emsam®)[2,7]

---

# Antipsychotics

**Use as directed**
- Asenapine (Saphris®)
- Lurasidone (Latuda®)
- Paliperidone (Invega®)
- Ziprasidone (Geodon®)

**Use with caution**
- Chlorpromazine (Thorazine®)[3,7]
- Clozapine (Clozaril®)[3,7,8]
- Fluphenazine (Prolixin®)[1]
- Olanzapine (Zyprexa®)[3,7]
- Perphenazine (Trilafon®)[3,7,8]
- Quetiapine (Seroquel®)[1]
- Risperidone (Risperdal®)[1,8]
- Thiothixene (Navane®)[2,7]

**Use with increased caution and with more frequent monitoring**
- Aripiprazole (Abilify®)[1,6,8]
- Haloperidol (Haldol®)[1,6]
- Iloperidone (Fanapt®)[1,6,8]
- Thioridazine (Mellain®)[3,6,7,9]

---

1. Serum level may be too high, lower doses may be required.
2. Serum level may be too low, higher doses may be required.
3. Difficult to predict dose adjustments due to conflicting variations in metabolism.
4. Genotype may impact drug mechanism of action and result in reduced efficacy.
5. Use of this drug may increase risk of side effects.
6. Serum level may be too low in smokers.
7. FDA label identifies a potential gene-drug interaction for this medication.
8. Per FDA label, this medication is contraindicated for this genotype.
“Stoplight” analogy greatly over-simplifies the content of results

Does NOT indicate which medication will be the best or most effective choice for a particular person!

No specific programs to ensure consistent dissemination of information to clinicians

Misinterpretation  Hesitation  Skepticism
Advantages

• Adjustments to dosing and titration rates
  • Decreased risk for intolerable side effects
  • Reasonable expectations for duration of action / efficacy

• Patient Buy-In
  • Validation for past negative responses to medications
  • More likely to adhere to regimen

• Possible cost reduction long-term
  • Avoiding less ideal medication trials
  • Decreased risk of adverse reactions leading to hospitalization
GeneSight® Psychotropic
COMBINATORIAL PHARMACOGENOMIC TEST

Patient, Sample
DOB: 7/22/1984
Order Number: 9904
Report Date: 6/22/2016
Clinician: Sample Clinician
Reference: 1456CIP

PATIENT GENOTYPES AND PHENOTYPES

PHARMACODYNAMIC GENES (PD)

SLC6A4
S/S
Reduced Response
This patient is homozygous for the short promoter polymorphism of the serotonin transporter gene. The short promoter allele is reported to decrease expression of the serotonin transporter compared to the homozygous long promoter allele. The patient may have a decreased likelihood of response to selective serotonin reuptake inhibitors due to the presence of the short form of the gene and may benefit from medications with an alternative mechanism of action.

HLA-B*1502
Present
Higher Risk
This patient carries either the HLA-B*1502 allele or a closely related *15 allele. Presence of HLA-B*1502 or some of the closely related *15 alleles suggests higher risk of serious dermatologic reactions including toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS) when taking certain mood stabilizers.

HTR2A
G/G
Increased Sensitivity
This individual is homozygous variant for the G allele of the -1438G>A polymorphism for the Serotonin Receptor Type 2A. They carry two copies of the G allele. This genotype has been associated with an increased risk of adverse drug reactions with certain selective serotonin reuptake inhibitors.

HLA-A*3101
A/T
Higher Risk
This patient is heterozygous for the A allele and the T allele of the rs1061235 A>T polymorphism indicating presence of the HLA-A*3101 allele or certain HLA-A*33 alleles. This genotype suggests a higher risk of serious hypersensitivity reactions, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), maculopapular eruptions, and Drug Reaction with Eosinophilia and Systemic Symptoms when taking certain mood stabilizers.

(Assurex Health, 2019)
**GeneSight Psychotropic**
**COMBINATORIAL PHARMACOGENOMIC TEST**

**Patient, Sample**
- **DOB:** 7/22/1984
- **Order Number:** 9904
- **Report Date:** 6/22/2016
- **Clinician:** Sample Clinician
- **Reference:** 1456CIP

**Questions? Call 855.891.9415 or email medinfo@assurexhealth.com**

**PATIENT GENOTYPES AND PHENOTYPES**

**PHARMACOKINETIC GENES**

### CYP1A2

**Genotype:** *1/*1

This genotype is most consistent with the extensive (normal) metabolizer phenotype.

### CYP2B6

**Genotype:** *1/*6

CYP2B6*1 allele enzyme activity: Normal  
CYP2B6*6 allele enzyme activity: Reduced

This genotype is most consistent with the intermediate metabolizer phenotype. This patient may have reduced enzyme activity as compared to individuals with the normal phenotype.

### CYP2C19

**Genotype:** *17/*17

CYP2C19*17 allele enzyme activity: Increased  
CYP2C19*17 allele enzyme activity: Increased

This genotype is most consistent with the ultrarapid metabolizer phenotype. This patient may have increased enzyme activity as compared to individuals with the normal phenotype.

### CYP2C9

**Genotype:** *1/*2

CYP2C9*1 allele enzyme activity: Normal  
CYP2C9*2 allele enzyme activity: Reduced

This genotype is most consistent with the intermediate metabolizer phenotype. This patient may have reduced enzyme activity as compared to individuals with the normal phenotype.

### CYP3A4

**Genotype:** *1/*1

CYP3A4*1 allele enzyme activity: Normal  
CYP3A4*1 allele enzyme activity: Normal

This genotype is most consistent with the extensive (normal) metabolizer phenotype.

### CYP2D6

**Genotype:** *4/*4 (Duplication)

CYP2D6*4 allele enzyme activity: None  
CYP2D6*4 allele enzyme activity: None

This genotype is most consistent with the poor metabolizer phenotype. This patient may have reduced enzyme activity as compared to individuals with the normal phenotype.

A duplication of the gene CYP2D6 has been detected in this patient. While current genotyping techniques allow for the detection of this duplication, in the case of heterozygosity, such techniques do not allow for the identification of the allele that has been duplicated. This duplication, depending on the allele duplicated, can result in increased expression of CYP2D6.

### UGT1A4

**Genotype:** *1/*1

UGT1A4*1 allele enzyme activity: Normal  
UGT1A4*1 allele enzyme activity: Normal

This genotype is most consistent with the extensive (normal) metabolizer phenotype. The patient is expected to have normal enzyme activity.

### UGT2B15

**Genotype:** *2/*2

UGT2B15*2 allele enzyme activity: Reduced  
UGT2B15*2 allele enzyme activity: Reduced

This genotype is most consistent with the intermediate metabolizer phenotype. This patient may have reduced enzyme activity as compared to individuals with the normal phenotype.
**GeneSight Psychotropic**

**COMBINATORIAL PHARMACOGENOMIC TEST**

**Patient, Sample**

DOB: 7/22/1984

Order Number: 9904

Report Date: 6/22/2016

Clinician: Sample Clinician

Reference: 1456CIP

---

### GENE-DRUG INTERACTIONS

**USE AS DIRECTED**

<table>
<thead>
<tr>
<th></th>
<th>CYP1A2</th>
<th>CYP2B6</th>
<th>CYP2C19</th>
<th>CYP2C9</th>
<th>CYP3A4</th>
<th>CYP2D6</th>
<th>UGT1A4</th>
<th>UGT2B15</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ANTIDEPRESSANTS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ANXIOLYTICS AND HYPNOTICS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ANTIPSYCHOTICS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>MOOD STABILIZERS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

### MODERATE GENE-DRUG INTERACTION

<table>
<thead>
<tr>
<th></th>
<th>CYP1A2</th>
<th>CYP2B6</th>
<th>CYP2C19</th>
<th>CYP2C9</th>
<th>CYP3A4</th>
<th>CYP2D6</th>
<th>UGT1A4</th>
<th>UGT2B15</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ANTIDEPRESSANTS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ANXIOLYTICS AND HYPNOTICS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- Variation was found in patient genotype that may impact medication response.
- This gene is associated with medication response, but patient genotype is normal.
Today’s Takeaways

• Psychiatric Conditions are multifactorial in origin, with current theories supporting suspicion for major role of epigenetics

• Pharmacogenomics is an area of interest for current and future research with the ultimate goal of “individualizing” treatment based on a person’s genetic code

• While pharmacogenomic testing can be helpful for making clinical decisions, the technology does not yet exist that would allow a clinician to determine the “best” treatment for a specific client.
References


Pictures

In order of appearance:

- https://www.healthyplace.com/other-info/mental-illness-overview/coming-to-terms-with-a-family-members-mental-illness
- http://www.mentalhealthamerica.net/b4stage4-get-informed
- https://carrington.edu/blog/student-tips/education/historical-overview-of-pharmacology/
- http://personalizedhealthsolutions.com/patients/medications/